AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00729547 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy placebo
Description: These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
Study NCT05018741 — intervention group
Intervention type: PROCEDURE
Intervention: liver transplantation
Description: liver transplantation for chronic liver disease or acute liver failure
Study NCT00957333 — intervention group
Intervention type: OTHER
Intervention: ketamine
Study NCT00635089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: reslizumab
Study NCT03518346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
Study NCT03518346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Books, movies, TV
Study NCT04518163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Intravenous 1 gm tranexamic acid in 100 ml saline by slow infusion before skin incision
Study NCT04518163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: Intravenous 110 ml saline by slow infusion before skin incision
Study NCT04518163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bakri Balloon
Description: Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
Study NCT04518163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bakri Balloon
Description: Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
Study NCT03997643 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy to all dissected areas
Description: Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
Study NCT03997643 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Omit radiation to pN0 neck
Description: post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
Study NCT00368121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab +/- Dexamethasone
Description: Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally
Study NCT02128945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F] - Fludarabine PET/CT
Description: \[18F\] - Fludarabine PET/CT before treatment
Study NCT02602665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shallow catheter tip placement
Description: for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
Study NCT02602665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep catheter tip placement
Description: deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
Study NCT03218579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic treatment
Description: 4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
Study NCT03218579 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacteriotherapy
Description: Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
Study NCT02358915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FastStart neuromuscular electrical stimulator
Study NCT03151928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BDMax Vaginal Panel
Description: The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
Study NCT01443663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Vaccine
Description: Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
Study NCT02290509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent
Description: Intramuscular injection of study vaccine
Study NCT02290509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV4)
Description: Intramuscular injection of study vaccine
Study NCT03040063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined endovascular approach (EVAR)
Description: 1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Heparin 70-80 IU/kg i.a.~5. implantation of peripheral stent graft VIABAHN~6. implantation of peripheral stent SUPERA into stent graft~7. insertion of strait flush catheter for local thrombolysis~8. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~9. control angiography in 12 hrs or earlier according to clinical status and symptoms~10. repeated angiography in 24 hrs
Study NCT01682811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Levulan surface application twice with microneedling
Description: Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
Study NCT01682811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1
Description: 2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
Study NCT01682811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2
Description: 2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
Study NCT01682811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
Description: 2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
Study NCT02443740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
Study NCT02443740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
Study NCT02443740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
Study NCT01840306 — intervention group
Intervention type: OTHER
Intervention: Biomarker Analysis
Study NCT01328522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191 (REGN88)
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study NCT00641446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Study NCT00641446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varicella zoster virus
Study NCT02443987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Description: 500ml infusion of 0.9% Sodium Chloride intravenously.
Study NCT04548765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Recipients receive a letter promoting CRC screening.
Study NCT04548765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Letter
Description: Recipients receive a letter promoting CRC screening.
Study NCT04548765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Frame and Fear Appeals
Description: The letter is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
Study NCT04548765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transparency
Description: The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
Study NCT04548765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Effect and Presentation of Alternatives
Description: The pros and cons for screening with FIT kits and colonoscopy are presented. By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer). In this situation, inaction is no longer the default option. Changing the default option increases the chance that the FIT kit is used. In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
Study NCT04548765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Fear Appeals and Decoy Effect
Description: Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed. Inaction is presented as a decoy, which has worse outcomes than either of the screening options. Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
Study NCT00420732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute-Lung Cancer Vaccine
Description: 300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
Study NCT02051556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy WSI
Description: Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
Study NCT02051556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy BSI
Description: Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
Study NCT02051556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy ST
Description: Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
Study NCT02565940 — intervention group
Intervention type: OTHER
Intervention: biopsy
Study NCT00202930 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: anti-CD20 (Rituximab)
Description: 4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
Study NCT01255137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg tab orally twice a day with food every 28 days
Study NCT01789216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Study NCT01789216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentinoids
Study NCT01789216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01950923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: Given PO
Study NCT01950923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01950923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo standard robotic partial nephrectomy
Study NCT01950923 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo standard robotic partial nephrectomy
Study NCT02013648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study NCT02013648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02013648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study NCT02013648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Study NCT02013648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Study NCT00825318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
Study NCT01762397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMK-S005
Study NCT01113736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloMEM™
Description: To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
Study NCT03040063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard optimal therapy (OPT)
Description: 1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Unfractionated heparin 70-80 IU/kg i.a.~5. insertion of strait flush catheter for local thrombolysis~6. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~7. control angiography in 12 hrs or according to clinical status and symptoms~8. repeated angiography in24 hrs~9. Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm.
Study NCT01385098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 and Calcium
Description: 1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
Study NCT00464841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural
Description: 0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
Study NCT00464841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tsui Test for intrathecal catheter
Description: 0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
Study NCT02135848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863
Study NCT02135848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01005355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B
Description: Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
Study NCT03235245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Ipilimumab
Description: nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
Study NCT03235245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Description: nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
Study NCT03235245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib
Description: encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
Study NCT03536689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amniotic fluid index
Description: Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
Study NCT00598585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra)
Description: 25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
Study NCT00598585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills 3X/day for 6 weeks
Study NCT01522391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPK-060 1% ointment
Description: DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
Study NCT01522391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DPK-060 ointment
Description: Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
Study NCT05752591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic testing
Description: Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
Study NCT04185194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: transmission of the drug molecules to the underlying muscles
Study NCT04185194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed ultrasound
Description: using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain
Study NCT04185194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: especially designed physical therapy program
Description: by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
Study NCT04185194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: especially designed physical therapy program
Description: by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
Study NCT02896959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Study NCT02067065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-anesthesiologist propofol sedation
Description: Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
Study NCT02067065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol sedation administered by an anesthesiologist
Description: Propofol sedation by an anesthesiologist
Study NCT02067065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated